New Research: Key Drivers of Growth for Bed Bath a
Post# of 301275
NEW YORK, Oct. 06, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bed Bath and Beyond Inc. (Nasdaq: BBBY ), The Finish Line, Inc. (Nasdaq: FINL ), Exelixis, Inc. (Nasdaq: EXEL ), Garmin Ltd. (Nasdaq: GRMN ), Juno Therapeutics, Inc. (Nasdaq: JUNO ), and Mattel, Inc. (Nasdaq: MAT ) including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
BBBY DOWNLOAD: http://Fundamental-Markets.com/register/?so=BBBY
FINL DOWNLOAD: http:// Fundamental-Markets.com/register/?so= FINL
EXEL DOWNLOAD: http:// Fundamental-Markets.com/register/?so= EXEL
GRMN DOWNLOAD: http://Fundamental-Markets.com/register/?so=GRMN
JUNO DOWNLOAD: http:// Fundamental-Markets.com/register/?so= JUNO
MAT DOWNLOAD: http:// Fundamental-Markets.com/register/?so= MAT
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Bed Bath and Beyond Inc. (Nasdaq: BBBY ), The Finish Line, Inc. (Nasdaq: FINL ), Exelixis, Inc. (Nasdaq: EXEL ), Garmin Ltd. (Nasdaq: GRMN ), Juno Therapeutics, Inc. (Nasdaq: JUNO ), and Mattel, Inc. (Nasdaq: MAT ) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today’s readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples . All information in this release was accessed September 25, 2017. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All amounts in millions (except per share amounts).
-----------------------------------------
BED BATH & BEYOND (BBBY) REPORT OVERVIEW
Certified Factual by Registered Analyst
Bed Bath & Beyond's Recent Financial Performance
For the three months ended May 27, 2017 vs May 28, 2016, Bed Bath and Beyond reported revenues of $2,742.14 vs $2,738.08 (up 0.15%), earnings per share of $0.53 vs $0.80 (down 33.8%). For the 12 months ended February 25, 2017 vs February 27, 2016, Bed Bath and Beyond reported revenues of $12,215.76 vs $12,103.89 (up 0.92%), diluted earnings per share $4.58 vs $5.10 (down 10.20%).
To read the full Bed Bath and Beyond (BBBY) report, download it here: http://Fundamental-Markets.com/register/?so=BBBY
-----------------------------------------
THE FINISH LINE (FINL) REPORT OVERVIEW
Certified Factual by Registered Analyst
The Finish Line's Recent Financial Performance
For the three months ended August 26, 2017 vs August 26, 2016, The Finish Line reported net sales of $469.35 vs $485.16 (down 3.3%), earnings per share of $0.07 vs $0.53 (down 86.8%), and dividends per share of $0.11 vs $0.10 (up 10.0%). For the 12 months ended December 31, 2016 vs December 31, 2015, The Finish Line reported net sales of $1,844.39 vs $1,798.98 (up 2.5%), diluted earnings per share ($0.44) vs $0.48 (down 191.7%).
To read the full Finish Line (FINL) report, download it here: http:// Fundamental-Markets.com/register/?so= FINL
-----------------------------------------
EXELIXIS (EXEL) REPORT OVERVIEW
Certified Factual by Registered Analyst
Exelixis' Recent Financial Performance
For the three months ended June 30, 2017 vs June 30, 2016, Exelixis reported revenue of $99.01 vs $36.25 (up 173.1%), earnings per share of $0.06 vs ($0.15) (up 140.0%). For the 12 months ended December 31, 2016, vs December 31, 2015, Exelixis reported revenue of $191.45 vs $37.17 (up 415.1%), diluted earnings per share ($0.28) vs ($0.77) (up 63.6%). Exelixis is expected to report earnings on November 2, 2017. The report will be for the fiscal Quarter ending September 2017. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $0.07. The reported EPS for the same quarter last year was $0.01.
To read the Exelixis (EXEL) report, download it here: http:// Fundamental-Markets.com/register/?so= EXEL
-----------------------------------------
GARMIN (GRMN) REPORT OVERVIEW
Certified Factual by Registered Analyst
Garmin's Recent Financial Performance
For the three months ended July 1, 2017 vs June 25, 2016, Garmin reported revenue of $816.89 vs $811.61 (up 0.65%), earnings per share of $0.91 vs $0.85 (up 7.06%). For the 12 months ended December 31, 2016 vs December 26, 2015, Garmin reported revenue of $3,018.67 vs $2,820.27 (up 7.03%), diluted earnings per share $2.70 vs $2.39 (up 12.97%). Garmin is expected to report earnings on 10/25/2017. The report will be for the fiscal Quarter ending September 2017. According to Zacks Investment Research, based on 9 analysts' forecasts, the consensus EPS forecast for the quarter is $0.66. The reported EPS for the same quarter last year was $0.75.
To read the full Ford (F) report, download it here: http://Fundamental-Markets.com/register/?so=GRMN
-----------------------------------------
JUNO THERAPEUTICS (JUNO) REPORT OVERVIEW
Certified Factual by Registered Analyst
Juno Therapeutic’s Recent Financial Performance
For the three months ended June 30, 2017 vs June 30, 2016, Juno Therapeutics reported net sales of $21.27 vs $27.60 (down 22.9%), earnings per share of ($0.96) vs ($0.64) (down 50%). For the 12 months ended December 31, 2016 vs December 31, 2015, Juno Therapeutics reported revenue of $79.36 vs $18.22 (up 335.6%), earnings per share of ($2.42) vs ($2.72) (up 11.0%). Juno Therapeutics is expected to report earnings on November 8, 2017. The report will be for the fiscal Quarter ending September 2017. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is ($0.88). The reported EPS for the same quarter last year was $(0.58).
To read the full Juno Therapeutics (JUNO) report, download it here: http:// Fundamental-Markets.com/register/?so= JUNO
-----------------------------------------
MATTEL (MAT) REPORT OVERVIEW
Certified Factual by Registered Analyst
Mattel's Recent Financial Performance
For the three months ended June 30, 2017 vs June 30, 2016, Mattel reported revenue of $974.48 vs $957.28 (up 1.8%), earnings per share of ($0.16) vs ($0.06) (down 166.7%), and dividends per share of $0.38 vs $0.38 (unchanged). For the 12 months ended December 31, 2016 vs December 31, 2015, Mattel reported revenue of $5,456.65 vs $5,702.61 (down 4.3%), diluted earnings per share $0.92 vs $1.08 (down 14.8%). Mattel is expected to report earnings on October 18, 2017. The report will be for the fiscal Quarter ending September 2017. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $0.58. The reported EPS for the same quarter last year was $0.70.
To read the full Mattel (MAT) report, download it here: http:// Fundamental-Markets.com/register/?so= MAT
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world’s leading brokerages for over a decade—and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Market’s roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets’ oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets’ roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by GlobeNewswire staff, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets’ Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@fundamental-markets.com.
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact: Andrew Duffie, Media Department Office: +1 667-401-0010 E-mail: andrew.duffie@fundamental-markets.com
© 2017 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@fundamental-markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
(0)
(0)